European Commission approves Abevmy, a bevacizumab biosimilar, to treat the same indications as the originator drug .- Biocom Biologics

Biocon Biologics announced that Abevmy, a biosimilar of bevacizumab and developed with Viatris Inc.( ex Mylan) has received marketing authorisation from the European Commission following a positive recommendation by the CHMP of the European Medicines Agency. The biosimilar is approved for metastatic colorectal cancer, metastatic breast cancer, non small cell lung cancer, glioblastoma, ovarian, cervical and renal cancer.